Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date	Title and Summary	View
Feb 01, 2011	PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients - PPMD awards $250,000 grant towards research program-
Jan 19, 2011	PTC THERAPEUTICS' PRESIDENT AND CEO ELECTED AAAS FELLOW SOUTH PLAINFIELD, NJ – January 19, 2011 – Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. (PTC), has been elected a Fellow of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society and publisher of the journal Science.
Dec 21, 2010	PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis - Trial completion is expected in 2011 -
Dec 01, 2010	Observational Data from One-Year Follow-up Study Validate Six-Minute Walk Distance as an Outcome Measure in Duchenne and Becker Muscular Dystrophy SOUTH PLAINFIELD, NJ – December 1, 2010 – Data published in the December issue of the medical journal Muscle and Nerve confirm the utility of six-minute walk distance (6MWD) as a clinically meaningful endpoint in dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular
Nov 15, 2010	PTC Publishes Results From Phase 2 Study of Ataluren in Children with Cystic Fibrosis - Data show that ataluren restores the production of functional CFTR protein -
Oct 26, 2010	PTC Therapeutics Initiates Phase 2 Clinical Trial of Ataluren in Patients with Methylmalonic Acidemia - First proof-of-concept clinical study of ataluren in a metabolic disorder -
Oct 15, 2010	PIVOTAL DATA PRESENTED AT THE WORLD MUSCLE SOCIETY CONGRESS SUGGEST ATALUREN SLOWS THE LOSS OF WALKING ABILITY IN PATIENTS WITH NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY - 29.7 meter average change in 6-minute walk distance compared to placebo at 48 weeks - - Safety results show ataluren was generally well tolerated - - Data to be the basis of interactions with regulatory authorities -
Sep 21, 2010	PTC THERAPEUTICS AWARDED $1.6 MILLION FDA ORPHAN DRUG GRANT TO SUPPORT AN ONGOING PHASE 3 STUDY IN CYSTIC FIBROSIS SOUTH PLAINFIELD, NJ – SEPTEMBER 21, 2010 – PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense
Jun 07, 2010	PTC THERAPEUTICS AWARDED $5.4 MILLION GRANT FROM THE WELLCOME TRUST -Over $100 Million in Cumulative Grant Funding Raised to Date-
Mar 03, 2010	PTC THERAPEUTICS AND GENZYME CORPORATION ANNOUNCE PRELIMINARY RESULTS FROM THE PHASE 2B CLINICAL TRIAL OF ATALUREN FOR NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY SOUTH PLAINFIELD, NJ and CAMBRIDGE, MA – March 03, 2010 – PTC Therapeutics, Inc. and Genzyme Corporation (Nasdaq: GENZ) today announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular